Table 1.
Metabolic risk factors at the study endpoint.
| Chow | WTD | WTD + Atorvastatin | |
|---|---|---|---|
| Body weight (g) | 25.9 ± 0.8 | 25.9 ± 0.3 | 25.5 ± 0.5 |
| Food intake (kCal/mouse/day) | 12.7 ± 0.2 *** | 11.3 ± 0.2 | 11.4 ± 0.1 |
| Plasma cholesterol (mM) | 2.4 ± 0.1 *** | 27.8 ± 1.6 | 15.8 ± 0.7 *** |
| Plasma triglycerides (mM) | 2.6 ± 0.2 ** | 5.0 ± 0.4 | 2.8 ± 0.2 *** |
| Liver weight (g) | 1.3 ± 0.1 *** | 2.5 ± 0.1 | 1.8 ± 0.1 *** |
| Plasma alanine transaminase (U/L) | 50.8 ± 6.0 *** | 283.2 ± 21.1 | 143.8 ± 16.5 *** |
| Plasma aspartate transaminase (U/L) | 110.2 ± 14.9 *** | 782.8 ± 48.2 | 521.2 ± 59.0 ** |
| Plasma serum amyloid A (µg/mL) | 11.6 ± 0.4 *** | 23.6 ± 1.6 | 13.7 ± 0.9 *** |
Data were determined at the study endpoint (t = 32 weeks) and are presented as mean ± SEM for n = 10 mice on chow, n = 16 mice on Western type diet (WTD) and n = 16 mice on WTD supplemented with atorvastatin. ** p < 0.01, *** p < 0.001 vs. WTD.